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POINT OF VIEW
Europe’s first and last field trial
of gene-edited plants?
Abstract On 5 June this year the first field trial of a CRISPR-Cas-9 gene-edited crop began at Rothamsted
Research in the UK, having been approved by the UK Department for Environment, Food & Rural Affairs. However,
in late July 2018, after the trial had started, the European Court of Justice ruled that techniques such as gene
editing fall within the European Union’s 2001 GMO directive, meaning that our gene-edited Camelina plants
should be considered as genetically modified (GM). Here we describe our experience of running this trial and the
legal transformation of our plants. We also consider the future of European plant research using gene-editing
techniques, which now fall under the burden of GM regulation, and how this will likely impede translation of
publicly funded basic research.
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Introduction
Agricultural production of oilseeds is steadily
increasing due to the high demand for food, ani-
mal feed and new industrial uses (USDA, 2018).
Innovation is required to meet market needs,
and also to facilitate a more sustainable use of
agricultural inputs, such as chemicals, fertilizers
and irrigation. To help address the challenges all
of this represents, we have been exploring the
genetic potential of the oilseed Camelina sativa.
This plant is native to Southeast Europe and
Southwest Asia and has an ancient history of cul-
ture, but was largely replaced by oilseed rape
(canola). However, in recent years, Camelina was
rediscovered as a promising crop due to its resil-
ience, relatively low agricultural input require-
ments, and resistance to biotic and abiotic
stresses (Guy and Ehrensing, 2008). Camelina
also presents an interesting oil profile for food,
feed and bio-based uses; it contains more than
50% polyunsaturated fatty acids (35% a-linolenic
acid) alongside tocopherols (Vitamin E), which
enhance oil stability (Nguyen et al., 2013).
Finally, Camelina is an excellent translational sys-
tem to validate new traits, since its genome is
closely related to the model plant Arabidopsis
thaliana (Kagale et al., 2014). Equally, ease of
genetic modification (Lu and Kang, 2008) allows
rapid development of new traits by conventional
as well as biotechnological modification either
by transgenesis or gene editing.
One specific trait of interest in oilseeds,
including Camelina, is increased levels of oleic
acid, a versatile and valuable monounsaturated
fatty acid with high oxidative stability
(Vanhercke et al., 2013). The market demand
for oleic acid-rich oils continues to grow in both
North America and Europe, predominantly as a
result of efforts to reduce the level of saturated
fatty acids in processed food (Watson, 2018).
Several strategies have been used to increase
the oleic acid content of Camelina seed oil,
including ethyl methanesulfonate (EMS)-muta-
genesis, suppression via RNA interference
(RNAi) and, more recently, CRISPR-Cas9 gene
editing (Kang et al., 2011; Nguyen et al.,
2013; Morineau et al., 2017; Jiang et al.,
2017). A clear target for modulation is the FAD2
D12-desaturase, which is the primary enzyme
responsible for the conversion of monounsatu-
rated oleic acid to diunsaturated linoleic acid.
Gene editing of FAD2 in the hexaploid Camelina
is particularly advantageous as it enables the
fine-tuning of oleic acid accumulation by select-
ing appropriate allelic combinations within the
three FAD2 homeologues present in the three
sub-genomes (Kang et al., 2011).
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Targeted disruption by CRISPR-Cas9 (pro-
grammed with two guide RNAs which recog-
nised sequences conserved in all three FAD2
homeologues) resulted in a population of Cam-
elina plants in which one or more FAD2 DNA
sequences were mutated. The triple knock-out
mutant plants (designated fad2 -/-/- to indicate
that all three homeologues were disrupted) had
the highest level of oleic acid and a develop-
mental phenotype with slow growth, twisted
leaves and delayed bolting when grown under
glasshouse conditions (Morineau et al., 2017).
This suggested that a reduction in polyunsatu-
rated fatty acids within the vegetative tissues
could impact agronomic performance. This is in
part due to the expression of FAD2 in both seed
and vegetative tissues and the disruption of this
in the GE lines. However, only field trials could
provide a real assessment of the relationship
between altered oleic acid levels and efficient
agronomic performance in these GE mutants.
To be able to study the plants in agriculturally
relevant conditions, we decided to proceed
toward field trial evaluation of these oleic-accu-
mulating GE Camelina lines. We compared wild-
type Camelina with two GE lines: the triple
fad2-/-/- line (designated A7) and a second line
(F4-24) in which two of the three FAD2 homeo-
logues are disrupted (fad2-/-/+). Unlike line A7,
the allelic combination in F4-24 did not perturb
the overall phenotype. In addition, we wished to
obtain clarity and precedent as to the regulatory
status of GE plants undergoing experimental
environmental release and field evaluation. Roth-
amsted Research has carried out successive GM
Camelina field trials since 2014, therefore we set
out to determine what official approvals would
be needed for a field trial of GE Camelina in the
UK, opening the process up for scientific learn-
ing and public scrutiny. More recently, it became
apparent that, while we were conducting our
trial, researchers at the Flemish Institute for Bio-
technology (VIB) were carrying out a nationally
authorised but covert field trial of GE maize in
Belgium. As a crucial difference, one goal of our
trial was to ensure that the issue of gene editing
and regulatory approval was very much in the
open and the focus of public discussion.
Status update
In absence of unambiguous information regard-
ing the regulatory status of GE plants, in
November 2017 we asked for clarification from
the Department for Environment, Food and
Rural Affairs (DEFRA), the UK competent author-
ity in this area. DEFRA sought advice from their
independent Advisory Committee on Releases
to the Environment (ACRE), asking them to con-
sider a number of points regarding our GE fad2
Camelina. Specifically, DEFRA sought clarifica-
tion on: (i) if these GE lines could have been pro-
duced by traditional breeding methods; (ii) if
Figure 1. Field trial of gene-edited Camelina. (A) Aerial view of the trial setting on 12 July 2018, 5 weeks after sowing with two blocks per line (GE lines
boxed in red – from left to right, plots are Control Celine, A7 and F4-24). Field irrigation was provided due to the unusually hot and dry UK summer. (B)
Gene-edited lines A7 and F4-24 with control Ce´line on 13 August 2018, 9 weeks after sowing (A7 dwarf phenotype in inset).
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they contained any DNA from the CRISPR-Cas9
transformation vector; and (iii) if the CRISPR-
Cas9 gene-editing technique was a form of
mutagenesis and how recombinant nucleic acid
molecules were used in the generation of these
plants.
These questions were likely prompted by the
Opinion provided by Advocate General Bobek
to the European Court of Justice (ECJ)
(Bobek, 2018) as part of ongoing deliberations
as to the status of new breeding techniques
such as gene editing. To help address some of
these points, we provided additional data as to
the presence or absence of the T-DNA insert,
based on gene-specific PCR and screening for
the visible marker DsRed which was also present
in the transgene cassette. ACRE considered
these points and also discussed them at an open
meeting on 23 March 2018. Their advice to
DEFRA, published on 18 May 2018
(ACRE, 2018), was that the mutations present in
the GE lines could have been produced through
traditional breeding techniques. Moreover,
although this mutagenesis involved recombinant
nucleic acids, these elements (e.g. Cas9 and
associated guide RNA) were no longer present
in the lines proposed for release. Therefore,
ACRE concluded that "it would not be possible
to determine whether these lines had been pro-
duced by genome-editing or by traditional
mutagenesis because they would be genetically
indistinguishable". As a result, DEFRA con-
cluded that the Camelina lines were not geneti-
cally modified organisms for the purposes of
Part VI of the Environmental Protection Act
(1990) as applied in England, and as such, there
was no requirement to seek consent from the
Secretary of State for Environment, Food and
Rural Affairs prior to their release. Presciently,
DEFRA also noted that this status might change
as a consequence of any ruling from the ECJ.
Contemporaneous to the discussion about
gene editing above, Rothamsted Research
applied to DEFRA on 20 February 2018 for con-
sent to carry out a new GM Camelina field trial.
This application, Genetically Modified Organ-
isms: Rothamsted Research (18/R08/01), sought
permission to evaluate 14 different GM Camel-
ina lines (predominantly engineered to accumu-
late omega-3 fish oils – see Usher et al., 2017).
The application was placed on the DEFRA web-
site for public comment for 48 days from the
date of submission. The application was also
publicised by advertisement in the national press
on 23 February and through a press release
from Rothamsted Research. As part of the
description of the trial layout, we included the
two GE lines, as they would be grown alongside
the GM lines and the wild-type control. The
application and any submissions from the public
consultation were considered by ACRE at their
open meeting on 23 March 2018, and on their
advice, consent for this GM trial was also
approved on 18 May 2018 (DEFRA, 2018). On
this basis, the fully authorised release of both
GM and GE Camelina could proceed.
Down on the farm
Seeds were sown in two 9 m2 blocks at a density
of 300 per m2 on 5 June 2018. The total area
sown was 2128 m2, with GM and GE plants con-
tributing a total of 306 m2. The GM and GE
Camelina were surrounded by a 6-metre-wide
pollen barrier of wild-type Camelina, with the
larger trial site secured with a deer-proof dou-
ble-fence (Figure 1A). As mentioned above, pre-
vious glasshouse studies of fad2 -/-/- GE
mutants had indicated that the resulting high
oleic content present in vegetative tissues per-
turbed development (Morineau et al., 2017).
Given the importance of polyunsaturated fatty
acids in membrane lipid functionality, it is unsur-
prising that the genetic inactivation of one of
the key desaturase enzymes results in pheno-
typic alterations. However, the phenotype
(severely dwarfed plants) observed in the field
was more extreme than that previously seen
under glasshouse conditions, emphasising the
importance of evaluation of plant performance
by actual field trials (Figure 1B). In this case, it
was clear that this particular allelic combination,
although generating a high oleic acid seed oil,
resulted in very significant growth defects,
meaning new allelic combinations should be
evaluated for less deleterious vegetative effects.
After sowing in early June, the trial pro-
gressed well. Away from the fields, the status of
the GE plants was being examined by the ECJ,
and 25 July 2018, just as the plants had finished
flowering and started to set seed, the ECJ pro-
nounced that new gene-editing technologies
such as CRISPR-Cas9 fell under the 2001 GMO
directive, meaning that our GE plants were now,
in the eyes of the ECJ, metaphorically (but not
literally) transformed into GM plants. In line with
their previous advice, we contacted DEFRA as to
the updated regulatory status of these GE
plants. DEFRA confirmed that the plants were
now considered GM and they would have to be
harvested and destroyed in the same way as the
authorised GM lines. Fortunately, due to
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experimental design, as opposed to regulatory
requirement, the GE lines were being grown
within the confines of the 18/R8/01 GM trial,
and therefore were managed in exactly the
same way as the GM lines. As a result, both trials
proceeded to a successful harvest and the GE
Camelina lines could be fully assessed for field
performance.
The making of a mutant
In the context of the new European classification
of GE plants, one could wonder how their regu-
latory status will be determined in practise.
While the presence or absence of a transgene is
easily monitored, GE plants will be only distin-
guished by the new mutation they carry. Even
for a small experimental GM field trial as
described here, the risk assessment which forms
the basis on which consent is given, focuses on
the different foreign DNA elements added to
the host [see Genetically Modified Organisms:
Rothamsted Research (18/R08/01) for full
details]. However, the GE plants under study in
this case do not contain any transgenes and, as
DEFRA noted in their advice, the mutations in
the FAD2 desaturase could have occurred by
traditional mutagenesis, or even natural varia-
tion. So what diagnostic technique could be
used to find a small deletion within an entire
genome, and perhaps more importantly, how
might one determine how this occurred? If gene
editing was used to recreate a mutation that was
already known to exist in nature, how could this
process be defined and traced? This conundrum
is one that will need to be urgently addressed
by the EU’s regulatory agencies, not least of all
if other countries and trading partners start the
commercial cultivation of GE commodity crops
and these are imported into Europe.
Strictly speaking, while most GE mutations
are indeed induced by the Cas9-mediated
sequence-specific cleavage, they were ultimately
produced by the plant DNA repair machinery in
a relatively random way, replicating "classical"
chemical or ionising radiation mutagenesis. In
the case described here, the CRISPR-Cas9 gen-
erated mutations in FAD2 displayed variations in
the size of the deletion, which lead to the differ-
ent mutant alleles (Morineau et al., 2017). Inter-
estingly, if not confusingly, mutations in the
FAD2 genes of soybean, rapeseed and sun-
flower have been previously selected to produce
high oleic acid cultivars that have been grown
for many years. The ECJ ruling stated that "only
organisms obtained by means of techniques/
methods of mutagenesis which have convention-
ally been used in a number of applications and
have a long safety record are excluded from the
scope of that [GMO] directive". Thus, the high
oleic acid Camelina lines described here differ
from the other high oleic acid crops only by the
mutagenesis process and not by the actual
mutations in FAD2 genes.
One of the virtues of the CRISPR-Cas9 system
is the precision by which it introduces a single
mutation, which is in stark contrast to conven-
tional breeding or mutagenesis which introduces
many. But, in the eyes of the ECJ, the multiple
mutations obtained by such techniques are
allowable simply on the basis of previous safe
use. Obviously, obtaining a "long safety record"
for growing these GE lines in the context of such
strict European regulation would be very diffi-
cult, if not impossible. But it is interesting to
note that this ECJ ruling might now encompass
plants that were generated without gene editing
or genetic modification but which do not have a
long history of use – this again could impede
innovation in the plant breeding sector. Ulti-
mately, the de facto reclassification of gene edit-
ing as a form of genetic modification presents
an enormous burden on researchers (public or
private) trying to convert their ideas into innova-
tions and impactful outcomes. Given that the EU
has only approved one new GM crop (BASF’s
Amflora potato) in the last decade (and even
that approval was subsequently annulled by
General Court of the European Union), the pipe-
line for translating the skills and know-how of
the EU research base in this sector looks
blocked, and equally unlikely to attract inward
investment. It is hard to believe that this is either
a desired or desirable outcome.
The importance of field trials
Field trials provide a tremendous amount of oth-
erwise unknown information on how plants
respond to environmental changes in the field,
under agricultural systems. Based on our recent
experience (Usher et al., 2017), and backed up
by a plethora of previous observations, it is vital
to move from controlled environment to the
field to validate any potentially interesting phe-
notype. If part of the ambition of basic plant sci-
ences research is to deliver to the needs of
agriculture and "feed the world" then there
needs to be a greater flux from growth cabinet
to field; also, there needs to be an appreciation
that performance in the first is no guarantee of
something similar in the field. In the case of GE,
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such edited plants have the potential to uncover
new and extremely useful traits for crops, nota-
bly in the context of more sustainable agricul-
ture, where a reduction in pesticides, fertilisation
and irrigation is desired. Only field trials can pro-
vide the environmental gauntlet to challenge
these new traits under realistic conditions and
allow for the selection of the most relevant
alleles.
In conclusion, the Rothamsted Camelina 2018
GE field trials provided a wealth of essential
data and enabled the evaluation of the potential
of new trait. Access to field trials are an essential
component in the demonstration of efficacy for
any new crop trait. Limiting the feasibility of GE
field trials by expanding the complexity of the
regulatory process and the associated financial
burden of dedicated experimental sites will cer-
tainly hinder research and limit the contribution
EU research can make to meet the challenge of
the UN’s Sustainable Development Goals. Sadly,
there is a general perception that carrying out
GM field trials is a burden that is best avoided.
However, based on our experiences at Roth-
amsted Research, not only do such trials provide
vital information as to the utility (or not) of a trait
(Bruce et al., 2015), they also provide a strong
focal point for science communication and pub-
lic engagement. Collectively, we must continue
to advance our understanding of plant sciences
and crop biology. Therefore, we strongly urge
that the scientific community continues to make
the case in Europe for access to research field
trials for the evaluation of GE and GM crops.
This needs to take the form of not just appropri-
ate infrastructure (which can range from some-
thing akin to the Swiss Federal Government
"Protected Site" at Reckenholz, the facilities at
Rothamsted Research or just a suitable field),
but also both financial and institutional support
to carry out such experiments. Thus, funding
agencies should not decline to support such
activities, and academic institutions should not
shrink from carrying them out. Otherwise, trans-
lation and innovation in plant sciences in Europe
will be significantly impaired.
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